Some cases of Chronic Myelomonocytic Leukaemia (CMML) have constitutive activation of the gene for PDGFRB (platelet derived growth factor receptor beta) which encodes a receptor tyrosine kinase1.
The activation is usually caused by a t(5;12)(q32;p13) translocation which results in the ETV6 (TEL)-PDGFRB fusion gene. Patients with this fusion have reportedly been shown to be responsive to the drug imatinib mesylate (Gleevec)1, which specifically inhibits the kinase activity of PDGFRB. The breakpoint in PDGFRB is characteristically located in intron 102,3.
1. Apperley JF et al., N Engl J Med 2002;347:481-7
2. Tokita K et al., Leukemia 2007;21:190-2
3. Levine et al., Leukemia 2005;19:27-30
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.